- Home
- ENPH vs PCVX Comparison
ENPH vs PCVX Comparison
Compare ENPH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | PCVX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.0B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ENPH | PCVX |
|---|---|---|
| Price | $51.46 | $51.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 4 |
| Target Price | $41.30 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 7.9M | 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $29.10 |
| 52 Week High | $73.74 | $65.00 |
Technical Indicators
Market Signals| Indicator | ENPH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 54.48 |
| Support Level | $32.08 | $44.85 |
| Resistance Level | $73.74 | $52.00 |
| Average True Range (ATR) | 5.44 | 2.12 |
| MACD | -2.23 | 0.73 |
| Stochastic Oscillator | 18.54 | 75.06 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.